YASTEST
DUBLIN - November 13, 2017 -
Medtronic plc (NYSE: MDT) today announced several noteworthy
presentations of clinical studies and symposia on aortic,
peripheral, endoVenous, and vascular embolization therapies at the
44th Annual
Symposium of Vascular and Endovascular Issues (VEITHsymposium), the
world's largest educational meeting specializing in vascular
surgical medicine in New York from November 14 - 18, 2017.
In a first-to-podium presentation, William Jordan,
M.D., professor of surgery and chief, Division of Vascular Surgery
and Endovascular Therapy at Emory University School of Medicine and
co-principal investigator of the ANCHOR registry, will report on
12-month results from the ANCHOR Registry evaluating the
FDA-approved Endurant(TM) II/IIs Stent Graft System in combination
with the Heli-FX(TM) EndoAnchor System in subjects with abdominal
aortic aneurysm (AAA) with aortic necks less than 10mm.
Frank R. Arko III, M.D., chief, Vascular and
Endovascular surgery, professor, Cardiovascular Surgery and
co-director, Aortic Institute, will present new 30-day clinical
outcomes on the investigational Valiant(TM) Navion device, a
minimally invasive thoracic endovascular aortic repair (TEVAR)
system for patients with descending thoracic AAA disease.
"At this year's VEITHsymposium, we are thrilled to
be able to feature nearly 40 different clinical presentations on
our aortic, peripheral, endoVenous, and vascular embolization
therapies, six of which are podium-firsts," said Jason Weidman,
senior vice president and president of the Aortic & Peripheral
Vascular division, which is part of the Cardiac and Vascular Group
at Medtronic. "The vast amount of data being featured this week
underscores our commitment to durable, consistent and safe vascular
procedures, as well as industry-leading clinical rigor and data
transparency."
A schedule of key data presentations and symposia
appear below in chronological order in Eastern Standard
Time. Some of the titles included in the presentations below
may include investigational devices or uses. All presentations will
be held at the New York Hilton Midtown.
Monday, November 13
1:00 p.m. - AIM Symposium: Treatment of Pelvic Reflux and Prostate
Artery Embolization
Location: Gramercy West
Moderator: Ripal Gandhi, M.D.
Speaker: Shivank Bhatia, M.D.
Tuesday, November
14
6:57 a.m. - DEBATE: Not So: With Modern Endografts and
Improved Techniques EVAR Outside IFUs Can Have Good Outcomes with
Low Rates of Endoleaks and Sac Growth
Session 9: Grand Ballroom East, Third Floor
Presenter: Dittmar Bockler, M.D.
11:39 a.m. - For Short Necked AAAs Standard EVAR Plus Fixing with
EndoAnchors is the Best Treatment for Many Patients; What Are the
Limits?
Session 12: Grand Ballroom West, Third Floor
Presenter: William Jordan, M.D.
Wednesday, November
15
12:00 p.m. - Symposium: Treating Simple to Complex Femoropopliteal
Lesions Through Luminal Gain and Drug-Coated Balloon
Technology
Location: Medtronic Pavilion, Third Floor
Moderator: Peter Schneider, M.D.
Speakers: Gunnar Tepe, M.D., William Gray, M.D., Eric Scott,
M.D.
Thursday, November
16
10:45 a.m. - Early Clinical Results and Experience with Next
Generation Valiant Navion Low-Profile TEVAR Device
Session 57: Grand Ballroom West, Third Floor
Presenter: Frank R. Arko III, M.D.
12:00 p.m. - Symposium: Expanding Patient Care Options
Location: Medtronic Pavilion, Third Floor
Moderator: Ross Millner, M.D.
Speakers: David Deaton, M.D., William Jordan, M.D., Frank R. Arko
III, M.D.
12:00 p.m. - Symposium: VenaSeal Closure System Panel Discussion:
The Procedure, The Patients and Your Practice
Location: Gramercy
Moderator: Brian Ferris, M.D.
Speakers: Kathleen Gibson, M.D., Joseph Ricotta, M.D., Manjit
Gohel, M.D.
3:25 - 4:12 p.m. - Concurrent EndoAnchor Sessions: Indication and
Value, EndoAnchors with TEVAR
Session 61: Grand Ballroom West, Third Floor
Moderators: Luis Sanchez, M.D., William Jordan, M.D.
In collaboration with leading clinicians,
researchers, and scientists worldwide, Medtronic offers the
broadest range of innovative medical technology for the
interventional and surgical treatment of cardiovascular disease and
cardiac arrhythmias. The company strives to offer products and
services of the highest quality that deliver clinical and economic
value to healthcare consumers and providers around the world.
About VEITHsymposium
Now in its 44th year, VEITHsymposium provides
vascular surgeons, interventional radiologists, interventional
cardiologists and other vascular specialists with a unique and
exciting format to learn the most current information about what is
new and important in the treatment of vascular disease. The 5-day
event features rapid-fire presentations from world renowned
vascular specialists with emphasis on the latest advances, changing
concepts in diagnosis and management, pressing controversies and
new techniques. Press will receive complimentary registration.
Please visit www.VEITHsymposium.org or contact Pauline T. Mayer at
+1-561-316-3330.
About Medtronic
Medtronic plc (www.medtronic.com) headquartered in Dublin, Ireland,
is among the world's largest medical technology, services and
solutions companies - alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 84,000 people worldwide, serving physicians,
hospitals and patients in approximately 160 countries. The company
is focused on collaborating with stakeholders around the world to
take healthcare Further, Together.
Any forward-looking statements
are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from
anticipated results.
-end-
Contacts:
Julia Baron
Public Relations
+1-858-692-2001
Ryan Weispfenning
Investor Relations
+1-763-505-4626
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medtronic plc via Globenewswire
Medtronic (NYSE:MDT)
Historical Stock Chart
From Apr 2024 to May 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From May 2023 to May 2024